Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations
Journal article published in 2022 by
Eugen Tausch,
Viktor Ljungström,
Andreas Agathangelidis,
Marc Zapatka 
,
Lydia Scarfò,
Billy Michael Chelliah Jebaraj,
Deyan Y. Yosifov ,
Annika Müller,
Veerendra Munugalavadla,
Jeremiah D. Degenhardt,
Paolo Ghia ,
Richard Rosenquist ,
Stephan Stilgenbauer
,
Lydia Scarfò,
Billy Michael Chelliah Jebaraj,
Deyan Y. Yosifov ,
Annika Müller,
Veerendra Munugalavadla,
Jeremiah D. Degenhardt,
Paolo Ghia ,
Richard Rosenquist ,
Stephan Stilgenbauer
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 